Current concepts of Harm–Benefit Analysis of Animal Experiments – Report from the AALAS–FELASA Working Group on Harm–Benefit Analysis – Part 1
Aurora Brønstad, Christian E. Newcomer, Thierry Decelle, Jeffrey I. Everitt, Javier Guillén, Kathy Laber
University of Bergen Sanofi (France) Research Triangle Park Foundation GlaxoSmithKline (United States)
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
International regulations and guidelines strongly suggest that the use of animal models in scientific research should be initiated only after the authority responsible for the review of animal studies has concluded a well-thought-out harm-benefit analysis (HBA) and deemed the project to be appropriate. Although the process for conducting HBAs may not be new, the relevant factors and algorithms used in conducting them during the review process are deemed to be poorly defined or lacking by committees in many institutions. This paper presents the current concept of HBAs based on a literature review. References on cost or risk benefit from clinical trials and other industries are also included. Several approaches to HBA have been discovered including algorithms, graphic presentations and generic processes. The aim of this study is to better aid and harmonize understanding of the concepts of 'harm', 'benefit' and 'harm-benefit analysis'.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Animal testing and alternatives
Ethics in Clinical Research
参考文献 47
此处列出前 3 条
引用本文 145
按被引量排序,此处列出前 3 条